A Two-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, and Effects on Histology and Different Clinical Parameters of Givinostat in Ambulant Children With Duchenne Muscular Dystrophy

Trial Profile

A Two-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, and Effects on Histology and Different Clinical Parameters of Givinostat in Ambulant Children With Duchenne Muscular Dystrophy

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Givinostat (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Therapeutic Use
  • Sponsors Italfarmaco
  • Most Recent Events

    • 23 Feb 2016 Planned End Date changed from 1 Aug 2015 to 1 Aug 2017, as reported by ClinicalTrials.gov.
    • 02 Dec 2014 Planned primary completion date changed from 1 Nov 2014 to 1 Dec 2014 according to ClinicalTrials.gov record.
    • 13 Aug 2014 New source identified and integrated (European Clinical Trials Database record: EudraCT2012-002566-12)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top